Jack A. RaghebMD, PhD
Dr Ragheb has been with Lilly for about 2 years and is based in Indianapolis where he is the Senior Medical Fellow in Global Patient Safety and Co-Chair of the Immunogenicity Immunosafety Working Group. He received his MD and PhD degrees from the Johns Hopkins University and is a Diplomate of the American Board of Allergy & Immunology. Formerly, he was a Senior Clinical Investigator at NIH where he conducted clinical and basic research on immune tolerance and a Chief Medical Research Officer in the Office of Biological Products at the FDA where his research group established the BLT humanized mouse model in an effort to predict the immunogenicity of biotherapeutics. He has published in the areas of immunogenicity, immune tolerance, CD28 and CD40L regulation, retrovirology and gene therapy.